PASSAGE BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
PASSAGE BIO, INC. (PASG) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $7.00 per share for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-09-03
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $7.64, a 1810.00% increase year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.40, a 72.97% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.48, a 37.04% increase year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.08, a 75.95% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.34, a 26.42% increase from fiscal 2023.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.06, a 65.70% decline from fiscal 2022.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $3.09, a 81.23% decline from fiscal 2021.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $16.46, a 8.72% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.00 S-4/A · filed 2026-09-03 | |||
| 2026-03-31 | $7.64 S-4 · filed 2026-07-21 | |||
| 2025-12-31 | $7.78 S-4/A · filed 2026-09-03 | |||
| 2025-09-30 | $7.78 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $7.78 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $0.40 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $1.34 10-K · filed 2025-03-04 | |||
| 2024-09-30 | $1.37 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $1.43 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $1.48 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $1.06 10-K · filed 2024-03-04 | |||
| 2023-09-30 | $1.06 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $1.08 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $1.08 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $3.09 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $3.37 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $3.42 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $4.49 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $16.46 10-K · filed 2022-03-03 | |||
| 2021-09-30 | $17.62 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $20.01 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $21.50 10-Q · filed 2021-05-05 | |||
| 2020-12-31 | $15.14 10-K · filed 2021-03-03 | |||
| 2020-09-30 | $14.81 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $14.61 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | $13.14 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $4.43 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |